Loading…
Chinese manufacturer of peptide active pharmaceutical ingredients used in diabetes, growth-hormone and other injectable drugs.
Chinese manufacturer of peptide active pharmaceutical ingredients used in diabetes, growth-hormone and other injectable drugs.
In one line: A small Chinese peptide-API supplier.
Moat: narrow (process know-how, regulatory licence). Peptide synthesis and purification know-how plus regulatory filings are costly to replicate quickly.
Headquarters: China · Employees: 2,360
Size Sinopep-Allsino Bio Pharmaceutical (688076.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.31B, the 1839th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥27.54 on 6 Nov 2026.
Performance Over six months the shares fell 7.4%, against -12.3% for the median peer and -16.4% for the China market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 14.1% over the last twelve months (peer median +15.5%); the operating margin is 18.6% (peer median 1.8%).
Valuation It trades at 12.5× forward earnings against a peer median of 19.2× (3rd cheapest of 7).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is -24 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.0 points above its cost of capital (6.1% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.16B | CN¥1.94B | CN¥1.62B | CN¥1.03B | CN¥642M |
| Revenue growth | — | +20% | +57% | +61% | — |
| Gross profit | CN¥1.42B | CN¥1.14B | CN¥1.04B | CN¥575M | CN¥330M |
| EBITDA | n/a | CN¥762M | CN¥670M | CN¥324M | CN¥176M |
| Net income | CN¥223M | CN¥332M | CN¥404M | CN¥163M | CN¥129M |
| Free cash flow | CN¥156M | -CN¥684M | -CN¥689M | -CN¥308M | -CN¥408M |
| Capital expenditure | CN¥856M | CN¥1.37B | CN¥1.09B | CN¥661M | CN¥438M |
| Total debt | CN¥3.16B | CN¥2.87B | CN¥1.79B | CN¥1.01B | CN¥384M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | $1.31B | -7% | +14% | 19% | 12.5× | 4.0% |
| Bachem BANB.SW | $7.32B | +3% | +5% | 19% | 33.1× | n/a |
| PolyPeptide PPGN.SW | $1.62B | +6% | +22% | 7% | 51.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688076.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.8% | -7.6% | 10th highest of 21 |
| 6-month return | -7.4% | -12.3% | 9th highest of 21 |
| Distance from 52-week high | -33.1% | -41.6% | 8th highest of 21 |
| Revenue growth (TTM) | +14.1% | +15.5% | 9th highest of 17 |
| Operating margin | 18.6% | 1.8% | 2nd highest of 17 |
| Forward P/E | 12.5× | 19.2× | 3rd cheapest of 7 |
| Growth the price implies (Req g, 7 yrs) | 4.0% | 4.4% | 4th least demanding of 7 |
| Growth delivered (Del g) | +27.9% | +13.3% | highest of 7 |
| Hurdle (Req g minus delivered) | -23.9 pp | -2.4 pp | least demanding of 7 |
| ROIC minus cost of capital | +4.0 pp | -5.2 pp | 2nd highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.31B | -7% | +14% | 19% | 12.5× | 4.0% | +27.9% |
| Voronoi 310210.KS | South Korea | $1.31B | -66% | +24% | -1,947% | n/a | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.32B | -12% | -3% | 1% | 19.7× | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.32B | -6% | -29% | 3% | 23.0× | 8.5% | -5.3% |
| Avalyn Pharma AVLN | United States | $1.29B | +7% | n/a | n/a | n/a | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.28B | +31% | n/a | n/a | n/a | n/a | n/a |
| Hanall Biopharma 009420.KS | South Korea | $1.34B | -25% | +5% | 3% | n/a | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $1.34B | -26% | +49% | 24% | 8.4× | -2.4% | +13.8% |
| Idorsia IDIA.SW | Switzerland | $1.34B | -5% | -5% | -70% | n/a | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.34B | +2% | +8% | 11% | 18.6× | 0.3% | -1.3% |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | n/a | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.34B | -18% | +17% | 13% | 9.1× | -7.4% | +12.7% |
| D&D Pharmatech 347850.KS | South Korea | $1.28B | -49% | -71% | -1,368% | n/a | n/a | n/a |
| GH Research GHRS | United States | $1.28B | -13% | n/a | n/a | n/a | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 50.3× | 26.1% | +23.1% |
| Nektar Therapeutics NKTR | United States | $1.27B | -54% | -27% | -239% | n/a | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.27B | -29% | +14% | 11% | n/a | 11.7% | +18.1% |
| LB Pharmaceuticals LBRX | United States | $1.36B | +31% | n/a | n/a | n/a | n/a | n/a |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.26B | -57% | +81% | -305% | n/a | n/a | n/a |
| MannKind MNKD | United States | $1.25B | +11% | +30% | 3% | n/a | n/a | n/a |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.37B | -32% | +21% | -127% | n/a | n/a | n/a |